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Abstract: Alphaviruses are enveloped single stranded RNA viruses, which as gene therapy 
vectors provide high-level transient gene expression. Semliki Forest virus (SFV), Sindbis 
virus (SIN)  and Venezuelan Equine Encephalitis (VEE) virus have been engineered as 
efficient replication-deficient and -competent expression vectors. Alphavirus vectors have 
frequently been used as vehicles for tumor vaccine generation. Moreover, SFV and SIN 
vectors  have  been  applied  for  intratumoral  injections  in  animals  implanted  with  tumor 
xenografts. SIN vectors have demonstrated natural tumor targeting, which might permit 
systemic vector administration. Another approach for systemic delivery of SFV has been to 
encapsulate replication-deficient viral particles in liposomes, which can provide passive 
targeting to tumors and allow repeated administration without host immune responses. This 
approach has demonstrated safe delivery of encapsulated SFV particles to melanoma and 
kidney  carcinoma  patients  in  a  phase  I  trial.  Finally,  the  prominent  neurotropism  of 
alphaviruses make them attractive for the treatment of CNS-related diseases.    
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1. Introduction 
Gene therapy has demonstrated some genuine promise during the last decade. For instance, the cure 
of  severe  combined  immune  deficiency  (SCID-X1)  patients  with  retrovirus  vectors  [1]  can  be 
considered a real success, despite the severe adverse events occurring in some patients [2]. These 
unexpected setbacks relate to the novelty of gene therapy and the shortcomings need to be addressed 
through intensive research. Other applications have been in the area of cancer, hemophilia and CNS 
disorders  [3].  Adenoviruses  are  commonly  used  viral  vectors  [4].  Moreover,  a  number  of  clinical 
studies have also been conducted with adeno-associated virus (AAV) [5]. Furthermore, retroviruses, 
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herpes simplex virus, vaccinia virus and more recently lentiviruses have been commonly utilized in 
animal models [6]. However, alphaviruses have not been explored in large extent for gene therapy 
applications, so far. Their special features and potential are described below. 
Alphaviruses are single-stranded RNA (ss-RNA) viruses with positive polarity [7]. They possess an 
envelope consisting of two or three major proteins forming heterologous spikes. Among the many 
alphavirus members, Semliki Forest virus (SFV) [8], Sindbis virus (SIN) [9] and Venezuelan Equine 
Encephalitis (VEE) virus [10] have been engineered as efficient delivery and expression vectors. The 
following types of vectors have been constructed (Figure 1): 1. Replication-deficient vector system, 
which usually comprises of two vectors, expression and helper vectors, although using split helper 
vectors  require  the  use  of  two  helper  vectors  [11].  The  expression  vector  contains  the  viral 
nonstructural genes responsible for replicase function of RNA. The structural genes have been deleted 
and  replaced  by  the  foreign  gene  of  interest.  Co-transfection  with  a  helper  vector  containing  the 
structural genes will provide the means for production of virus particles. However, due to the presence 
of the RNA packaging  signal only  on the expression vector, the  generated virus particles will be 
replication-deficient.  Although  no  new  virus  progeny  will  be  generated  upon  infection  with  these 
particles, they will generate high level transgene expression in target cells. 2. Replication-proficient 
vector system, which contains the full-length alphavirus genome and the additional foreign gene of 
interest.  These  vectors  provide  heterologous  gene  expression  as  well  as  generation  of  new  virus 
progeny.  The  advantage  of  replication-proficient  vectors  is  their  prolonged  expression  profile  and 
possibility to extend the infection to neighboring cells in vivo. On the other hand, these vectors pose a 
greater  safety  risk.  3.  Layered  DNA-RNA  vector  system  has  the  SP6  RNA  polymerase  promoter 
replaced by a CMV promoter, which will allow direct application of the vector as a transfection agent. 
Due to the presence of the SFV replicase genes, the extensive RNA replication will result in superior 
gene  expression  compared  to  conventional  plasmid  vectors.  Moreover,  as  no  virus  particles  are 
produced  at  any  stage,  the  safety  aspects  are  very  high.  In  contrast,  relying  on  only  transfection 
methods significantly compromises the gene delivery efficacy.  
Alphavirus  vectors  have  been  used  in  a  number  of  applications  [12].  Recombinant  protein 
expression has been established for activity and functionality determinations and a special emphasis 
has  been  dedicated  to  membrane  proteins.  Specifically,  SFV  vectors  have  been  employed  for  the 
expression of G protein-coupled receptors (GPCRs) and ion channels in various mammalian cell lines 
[13]. Moreover, the high infection rate of neuronal cells has made alphavirus vectors attractive tools in 
neuroscience. In this context, studies on location, transport and function of recombinant proteins have 
been conducted in primary neurons [14] as well as in hippocampal slice cultures [15]. Moreover, 
intracranial administration resulted in local transient reporter  gene expression with no visible side 
effects in rodents [16]. Large-scale protein production in mammalian suspension cultures in spinner 
flasks and bioreactors has provided recombinant GPCRs for drug screening projects and structural 
biology. For instance, in a structural genomics initiative, 101 GPCRs were expressed in 3 mammalian 
cell lines from SFV vectors [17]. In this review, the focus will be on the application of alphavirus 
vectors for gene therapy.     
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Figure 1. Alphavirus expression systems. (1.) Replication
vectors  (expression  and  helper  vectors)  are  required  fo
particles. The SP6 RNA polymerase promoter is utilized for 
the  subgenomic  26S  promoter  for  transgene  and  structural  gene  expression.
Replication-competent vector system: 
additional 26S subgenomic promoter drives the expression of the foreign gene. The foreign 
gene  can  be  placed  upstream  or  downstream  of  the  structural  genes.
layered vector system: A single vector where the SP
replaced by a CMV promoter allows a direct transient transfection approach.
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effect the transient expression mode of alphaviruses is not ideal. The recent engineering of replication-
competent oncolytic viruses may address this question to some extent. 
2.1. Vaccines 
Application of alphavirus vectors for vaccine generation has included SFV, Sindbis virus and VEE 
virus administered as replication-deficient virus particles, naked RNA and layered DNA-RNA vectors 
[18]. The main application has been for vaccine development against viruses in which vaccination with 
various viral surface expressing antigens has resulted in immunity and protection against challenges 
against lethal doses of pathogenic viruses in animal models. Additionally, a number of studies have 
described tumor vaccine development [19-24] (Table I). In this context, all three types of expression 
vectors have been applied. Different target genes such as interleukin-12 (IL-12) [19], human papilloma 
virus (HPV) E6 and E7 [20, 21], P815A tumor antigen [22] and the PIA gene [25] have been used. 
Interestingly, vaccination with naked SFV RNA replicons expressing bacterial β-galactosidase led to 
therapeutic efficacy and even protection in vaccinated mice [26]. As little as 1 µg of SFV-LacZ RNA 
provided  complete  tumor  protection  and  even  when  tumors  were  injected  two  days  prior  to 
immunization, the survival of mice was extended by 10-20 days compared to control animals [26]. 
Likewise, protection against P185 tumor challenges was obtained after vaccination with SFV particles 
expressing  the  P1A  gene  [25].  Mice  were  also  protected  from  new  tumor  development  after 
immunization with VEE vectors expressing the HPV-E7 gene [27]. An interesting approach was to 
subject isolated dendritic cells from mouse bone marrow to SFV particles expressing B16 and 203 
tumor antigens, which demonstrated protection against B16 and 203 gliomas and also prolonged the 
survival of animals with established tumors [28]. The DNA-RNA layered Sindbis vector was used to 
overexpress the murine melanoma cell adhesion molecule (MCAM/MUC18) for vaccination against 
B16F10 murine melanoma cells [29]. The vaccination led to efficient protection of mice from lethal 
challenges with melanoma-expressing murine MUC18 in both primary and metastatic tumor models. 
This  could  present  an  excellent  strategy  for  the  future  prevention  and  treatment  of  melanoma.  In 
another  application,  VEE  particles  carrying  the  truncated  neu  oncogene  were  used  to  transduce 
dendritic cells (DCs), which induced robust neu-specific CD8
+ T-cell and anti-neu IgG responses [30]. 
It was also demonstrated that a single administration of VEE-transduced DCs resulted in the regression 
of  large  established  tumors  in  mice.  VEE  particles  have  also  been  applied  for  prostate-specific 
membrane antigen (PSMA) immunotherapy [31]. Mice vaccinated with VEE-PSMA particles showed 
robust T-cell and B-cell responses after a single injection and anti-PMSA were detected after three 
immunizations.  VEE-PSMA  particles  induced  more  immunogenic  responses  than  purified  PSMA 
protein-adjuvants. Recently, it was demonstrated in transgenic mice, tolerant for HPV16-E6E7, that 
SFV-IL12 also stimulated SFV-HPV E6-E7-induced CTL responses [32].  
2.2. Cancer Therapy 
The main gene therapy applications of alphaviruses have dealt with cancer animal models. In this 
context,  the  most  popular  approach  has  been  intratumoral  injection  of  alphavirus  vectors  carrying 
reporter and/or therapeutic genes. For instance, SFV vectors expressing the p40 and p35 subunits of 
interleukin-12  (IL-12)  showed  significant  tumor  regression  and  inhibition  of  tumor  blood  vessel Viruses 2009, 1 
 
 
17 
formation  in  a  murine  B16  tumor  model  [33].  Furthermore,  SFV-GFP  particles  demonstrated 
substantial  reduction  in immunodeficient  mice  in  implanted  human  lung  tumors  after  intratumoral 
injections  [34]  indicating  that  the  SFV  particles  as  such  had  therapeutic  effect.  This  finding  was 
confirmed by the treatment of rapidly growing K-BALB and CT26 tumors with SFV particles, which 
resulted in apoptosis induction [35]. The expression of IL-12 [36] and IL-18 [37] from SFV vectors 
resulted in complete regression of K-BALB tumors in BALB/c mice and therapeutic efficacy in CT26 
tumors, respectively. In these studies, an SFV vector containing the translation enhancement signal 
from  the  capsid  gene  was  applied  to  provide  10  times  higher  transgene  expression.  In  another 
application, the expression of the murine vascular endothelial growth factor receptor-2 (VEGF-2) from 
SFV vectors led to the inhibition of angiogenesis, which reduced tumor growth and metastasis in mice [38].   
2.3. Oncolytic Vectors 
Replication-competent  alphaviruses  have  been  engineered  in  attempts  to  prolong  the  effect  of 
transgene expression and to enhance distribution in vivo. The avirulent SFV strain A7(74) has been the 
basis for the VA7-EGFP construct as illustrated in Figure 1. It was demonstrated that VA7-EGFP 
efficiently infected and lysed a number of cancer cell lines [39]. In SCID mice grafted with human 
melanomas a single injection (intratumoral, intraperitoneal or intravenous) of 10
6 pfu virus resulted in 
significant tumor  regression. Not surprisingly,  histological examination showed that in addition to 
tumor tissue the virus was present in normal tissue including the brain. The oncolytic VA7-EGFP 
vector was evaluated in human osteosarcoma xenografts in a nude mouse model [40]. Treatment with 
VA7-EGFP resulted in significant regression of tumors. In an orthotopic osteosarcoma nude mouse 
model with highly aggressive tumor growth oncolytic SFV extended the survival although no animal 
was finally cured. The oncolytic VA7-EGFP virus was also evaluated in an orthotypic lung cancer 
tumor model in nude mice [41]. In this study, VA7-EGFP was capable of providing a significantly 
increased survival rate comparable to achievements with a conditionally replicating Adenovirus (Ad5-
 24TK-GFP). However, the systemic administration of oncolytic virus demonstrated limited efficacy 
and requires further improved vectors. 
2.4. CNS Applications 
The neurotropic nature of alphaviruses has made them attractive vectors for the treatment of CNS-
related diseases. However, the neurovirulence of many SFV vectors has limited their applications in 
the CNS and has switched the focus to avirulent strains [42]. In this context, it was shown that VA7-
EGFP  (based  on  the  avirulent  strain  A7(74)  resulted  in  reduced  GFP  expression  in  neurons,  but 
enhanced presence in glial cells [43]. In vivo studies in rat [14] and mouse [44] brain demonstrated 
transient  local  reporter  gene  expression  after  stereotactic  injections  into  amygdala,  striatum  and 
substantia nigra. However, in the mouse brain cell degeneration and axonopathy [44], an indication of 
neuronal loss, was observed only for the wild type SFV vector, suggesting that less cytotoxic vectors 
such as A7(74) are required for successful CNS gene therapy. 
SFV  vectors  have  been  evaluated  in  experimental  autoimmune  encephalomyelitis  (EAE)  in  the 
mouse CNS induced by injection of myelin as an animal model for multiple sclerosis. Previously, it 
had  been  shown  that  SFV  is  capable  of  infecting  the  CNS  via  the  olfactory  bulb  after  intranasal Viruses 2009, 1 
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delivery [45]. Balb/c mice subjected to intranasal administration of SFV-EGFP particles demonstrated 
reporter gene expression in the olfactory bulb already after one day and it lasted for seven days [46]. 
When  mice  induced  for  EAE  were  intranasally  injected  with  SFV  particles  expressing  IL-10,  the 
clinical EAE was significantly reduced whereas SFV-EGFP and empty SFV vectors exacerbated the 
disease. In another study, SFV particles were employed for intranasal administration of interferon β 
(IFN β) [47]. In this case, inhibition of EAE was dependent on the timing of SFV administration and 
the number of injections. Furthermore, the avirulent SFV strain A7(74) was applied for the expression 
of the transforming growth factor β [48] and the inhibitor of metalloproteinase 2 [49] in mice. Despite 
intraperitoneal administration, the vector was able to cross the blood-brain barrier and demonstrated 
efficacy in inhibiting EAE.  
2.5. Mutant Vectors 
Several attempts have been made to further improve alphavirus vectors especially addressing the 
cytotoxicity of existing vectors and relatively short duration of transgene expression. In this context, 
Sindbis virus vectors with point mutations in the nonstructural gene nsP2 were shown to significantly 
reduce the cytotoxic effect on host cells [50, 51]. The point mutation P726S in nsP2 not only reduced 
the  cytoxicity,  but  also  enhanced  expression  levels.  Furthermore,  the  combination  of  the  P726S 
mutation  with  a  point  mutation  in  nsP4  resulted  in  a  less  cytotoxic  and  temperature-sensitive 
phenotype [52]. Similarly, point mutations introduced into the SFV vector has managed to reduce the 
cytoxicity. For instance, two point mutations in nsP2 (S259P, R650D) resulted in substantially reduced 
cytotoxicity  and  enhanced  transgene  expression  [53].  A  point  mutation  at  position  713  in  nsP2 
produced a replication-persistent phenotype in BHK cells [54]. The combination of the S259P, R650D 
and  L713P  resulted  in  reduced  cytotoxicity,  temperature-sensitivity  and  prolongation  of  gene 
expression [55]. Also, the combination of the mutations R649H and P718T generated an SFV vector 
which showed 100-fold lower RNA levels compared to wildtype vector although the β-gal levels were 
similar [56]. 
As described above, the nonstructural genes (nsP1-4) of the avirulent SFV strain A7(74) have been 
the basis of an expression vector, which showed a temperature-sensitive phenotype in BHK cells [43]. 
Moreover, studies in hippocampal slice cultures demonstrated highly specific expression in glial cells 
at 37°C, but reporter gene expression almost uniquely in neurons at 31°C.     
2.6. Targeting of Viral Particles 
The broad host range of alphaviruses and not the least due to their preference to target the CNS [6] 
has resulted in attempts to target the virus to the therapeutic cell/tissue of interest. Already more than 
10 years ago chimeric Sindbis virus particles were engineered by the introduction of IgG binding 
domains of protein A in the E2 Sindbis envelope [57]. This approach resulted in a 10
5-fold reduction 
of  infection  efficacy  of  BHK  cells,  but  allowed  enhanced  infection  rates  of  cells  treated  with  a 
monoclonal  antibody  against  surface  proteins.  More  recently,  it  was  discovered  that  Sindbis  virus 
possesses natural targeting to tumors [58]. Intraperitoneal injections showed specific reporter gene 
expression in implanted tumors in mice. Moreover, subcutaneous daily injections of SIN-IL12 virus Viruses 2009, 1 
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reduced the tumor load to 6.2% of control animals. Most astonishingly, intraperitoneal injections of 
SIN-Luc virus resulted in tumor targeted expression in spontaneous fibrosarcomas in the mouse tail. 
Table 1. Application of alphavirus vectors for generation of tumor vaccines. 
Target  Gene  Vector/Delivery  Response  Ref 
Brain tumor  IL-12  SFV/particles  Immunogenicity  [19] 
Cervical cancer  HPV E6-E7  SFV/particles  Tumor protection  [20] 
Glioma  B16, 203  SFV/particles  Tumor protection  [28] 
Tumor  β-gal  SFV/RNA  Tumor protection  [26] 
Tumor  HPV E7  VEE/particles  Tumor protection  [27] 
Tumor  HPVE7-VP22  SIN/particles  CD8
+ T-cell response  [21] 
Tumor  P815A  SFV/particles  Tumor protection  [22] 
Tumor antigen  MHC Class II  SFV/particles, DNA  Immunogenicity  [23] 
Tumor antigen  P185  SFV/particles  CTL, tumor protection  [25] 
Tumor antigen  Tyr-related prot-1  SIN/DNA  Antitumor activity  [24] 
Melanoma  MUC18  SIN/DNA  Tumor protection  [29] 
Tumor  Neu  VEE/particles  Tumor protection  [30] 
Prostate cancer  PSMA  VEE/particles  Immunogenicity  [31] 
β-gal, β-galactosidase; CTL, Cytotoxic T-lymphocyte activity; HPV, human papilloma virus; IL, 
interleukin; MHC, major histocompatibility complex; MCAM, melanoma cell adhesion molecule; 
PSMA, prostate-specific membrane antigen;  SFV, Semliki Forest virus; SIN, Sindbis virus; VEE, 
Venezuelan equine encephalitis virus. 
 
As no similar natural targeting to tumors has been observed for SFV, another approach to achieve 
targeting has been to encapsulate SFV particles in liposomes [59]. Efficient encapsulation of SFV-
LacZ  particles  was  obtained  and  systemic  delivery  in  SCID  mice  with  implanted  tumors  showed 
targeted  β-gal  expression  in  tumors.  The  systemic  delivery  was  demonstrated  safe  by  extensive 
histological  and  toxicological  analysis.  These  findings  set  the  basis  for  a  clinical  trial  applying 
encapsulated SFV-particles as described below. 
2.7. Clinical Trials for Alphaviruses 
Alphaviruses have obviously been used to a lesser extent in clinical trials compared to for instance 
retrovirus and adenovirus vectors. Despite this, a number of clinical trials have been completed or 
initiated [60]. Most of these trials are phase I safety trials in healthy volunteers using VEE replicons. 
AlphaVax has sponsored one vaccine trial for Cytomegalovirus (CMV) expressing the CMV proteins 
gB, pp65 and IE1. In another study, the influenza hemagglutinin (HA) protein was expressed from 
VEE vectors and evaluated as an influenza vaccine. The National Institute for Allergies and Infectious 
Diseases (NIAID) has sponsored a safety study on an HIV gag vaccine expressed from the VEE vector 
in healthy uninfected volunteers. Currently, recruiting is in progress for an immunotherapy study with 
VEE-CEA(6D) vectors in patients with advanced or metastatic CEA expressing malignancies.    
A  phase  I  clinical  trial  in  melanoma  and  kidney  carcinoma  patients  was  conducted  with 
encapsulated SFV particles expressing the p40 and p35 subunits of IL-12 [61]. The study showed no 
liposome- or SFV-related toxicity. The maximum tolerated dose (MTD) was determined to 3 x 10
9 Viruses 2009, 1 
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encapsulated  particles  per  m
2,  which  was  strongly  influenced  by  the  high  transient  expression  of 
recombinant IL-12 resulting in a fever response. The plasma IL-12 levels showed a 5-fold increase, 
which lasted for 4-7 days. Due to the liposome-encapsulation, SFV particles were not recognized by 
the host immune defense system and allowed therefore repeated systemic administration. The phase I 
study clearly demonstrated that encapsulated SFV vectors can be safely administered systemically to 
cancer patients. Despite the protocol for a phase I/II trial for the treatment of recurrent glioblastoma 
multiforme with encapsulated SFV vectors published in 2003 [62], the study has not been conducted. 
3. Conclusions 
Alphavirus vectors have showed versatility in gene therapy applications. The most frequently used 
vectors are based on SFV, Sinbis and VEE. In the future, also other alphaviruses might be developed 
into  functional  expression  vectors.  The  replication-deficient,  replication-competent  and  DNA-RNA 
layered vectors provide alternative delivery approaches. Furthermore, naked RNA has been shown 
feasible  for  immunization  in  vaccine  development.  Alphaviruses  have  been  used  for  vaccine 
development  approaches  to  establish  both  therapeutic  and  prophylactic  efficacy  against  tumors. 
Moreover,  alphavirus  vectors  have  been  evaluated  in  a  variety  of  animal  tumor  models  by 
intratumoral, intraperitoneal and intravenous administration. Efforts have been taken to target vectors 
to tumors by introduction of targeting sequence in the viral envelope or by encapsulation of viral 
particles in liposomes. Due to the efficient CNS delivery, alphavirus vectors have been evaluated to a 
limited  extent  as  therapeutic  vectors  in  animal  models  of  CNS  disease.  There  are  certainly  some 
limitations related to the applications of alphavirus vectors. Their transient expression profile makes it 
difficult to foresee any serious treatment of chronic diseases, where long-term or even life-long gene 
expression is generally required. The cytotoxic effect of alphaviruses must also be considered as a 
limitation, although it can be turned into an advantage in cancer therapy. The broad host range and 
especially the strong neurotropism certainly raise questions of concern about safety. Moreover, the 
lack of appropriate packaging cell lines will limit GMP production for clinical trials.      
For future applications of alphaviruses as gene therapy vectors most of the limitations mentioned 
above, except long-term expression, can be addressed through additional research and development. 
Despite the engineering of a number of mutant alphavirus vectors with improved features compared to 
wild type vectors, there is still a possibility for additional improvement such as reduced cytotoxicity 
and  prolonged  expression  profiles.  Additional  engineering  of  targeted  alphavirus  vectors  will  be 
beneficial.  The  engineering  of  an  appropriate  packaging  cell  line  is  necessary  to  ensure  GMP 
production of vectors for clinical trials.      
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